Resalis Therapeutics
Manufacturing · Italy · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Via Ettore De Sonnaz 19, Torino, Emilia-...Website
www.resalistherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Resalis Therapeutics
Resalis Therapeutics is focused on developing RNA-based therapies to address the root causes of complex metabolic disorders. The company is advancing its lead candidate, RES-010, which is designed to provide safe and effective treatment for obesity and fatty liver disease. With strong preclinical data, RES-010 is currently undergoing evaluation in a Phase 1 clinical trial, positioning Resalis as a significant player in obesity treatment. Their expertise in non-coding RNA and lipid metabolism underpins their innovative approach to improving metabolic health.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Resalis Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Resalis Therapeutics launches new products
Check out if Resalis Therapeutics is spiking on competitors!
Resalis Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Resalis Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Resalis Therapeutics
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Resalis Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Resalis Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Resalis Therapeutics has new funding data
Recommended Actions
Reach out to Masked Content who joined Resalis Therapeutics as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Resalis Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Resalis Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Resalis Therapeutics.
Resalis Therapeutics financials insights
Gather financial insights about Resalis Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Angel/Seed
$10.6M
2024
Series A
$11M
Resalis Therapeutics Tech Stack
A closer look at the technologies used by Resalis Therapeutics
Most Recent Scoops
Funding
Funding
New Hire
Executive Move
Funding
New Hire
Executive Move
Executive Moves
Resalis Therapeutics News & Media
Resalis Announces Initiation of Phase 1b Clinical Study Evaluating RES-010 as Treatment to Address Unmet Needs in Obesity
Torino, Italy, June 29, 2026 – Resalis Therapeutics today announced the dosing of the first participant in a Phase 1b clinical study of its lead candidate, RES-010, a novel antisense oligonucleotide targeting microRNA-22 (miR-22), designed to address the underlying drivers of obesity by targeting metabolic dysfunction to deliver durable, fat-selective weight loss with lean mass preservation. The study will investigate the effect of RES-010 on body weight loss and other weight loss-related parameResalis Therapeutics Appoints Sandor Batkai as Medical Director
Torino, Italy, January 22 – Resalis Therapeutics, a biotechnology company pioneering microRNA-targeted therapies, today announced the appointment of Sandor Batkai, MD, PhD, as Medical Director. Dr. Batkai is a physician-scientist with 20+ years in cardiovascular, metabolic and RNA therapeutics research and early development, and most recently served as Co-founder & Head of Medical Research & Intelligence at Cardior Pharmaceuticals. At Resalis, Dr. Batkai will be responsible for the strategy, desGLP-1 killer? Oligo therapy hits obesity at its source - BioXconomy
An ASO from Resalis Therapeutics reportedly offers precision weight loss along with a host of other potential benefits.Resalis Therapeutics Reports Durable, Fat-Selective Weight Loss with RES-010 in Non-Human Primates at Multiple Scientific and Industry Meetings
Torino, Italy, October 7 – Resalis Therapeutics, a biotechnology company pioneering microRNA-targeted therapies, presented new preclinical results on its lead candidate RES-010, a first-in-class antisense oligonucleotide targeting microRNA-22 (miR-22). The data was presented at the European Association for the Study of Diabetes (EASD) in Vienna, Austria, the Obesity Science & Innovation Meeting in Boston, MA, and the Obesity Drug Development Summit Europe in Barcelona, Spain. The study evaluated
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Resalis Therapeutics
Sign Up For FreeTo access detailed company insights
Resalis Therapeutics is focused on developing RNA-based therapies to address the root causes of complex metabolic disorders. The company is advancing its lead candidate, RES-010, which is designed to provide safe and effective treatment for obesity and fatty liver disease. With strong preclinical data, RES-010 is currently undergoing evaluation in... Read More
